EFEKTIFITAS PEMBERIAN RISPERIDONE TERHADAP SKOR PANSS DAN KADAR INTERLEUKIN 6 PADA PASIEN SKIZOFRENIA YANG TERKONFIRMASI COVID-19 = The Effectiness of Risperidone to PANSS score and IL-6 in Confirmed COVID-19 Schizophrenic Patients

Dessy Natalia, The Effectiness of Risperidone to PANSS score and IL-6 in Confirmed COVID-19 Schizophrenic Patients. (Supervised by Sonny Teddy Lisal, Hawaidah, Arifin Seweng)

Objective: The purpose aim of the study was to determine the effectiveness of risperidone on PANSS scores and Interleukin 6 (IL-6) levels in Schizophrenia patients with confirmed COVID-19.
Methods: The type of this study was analytical observational with a prospective cohort design. The subjects were inpatient Schizophrenia patients with and without COVID-19, mild-moderate and asymptomatic COVID-19 and schizophrenic patients without COVID-19 who were hospitalized and met the inclusion and the exclusion criteria with a total subjects of 22 for each group. Consecutive sampling the study instruments were the Positive and Negative Syndrome Scale (PANSS) and Elisa Interleukin 6 (IL-6) serum. Results: In the positive COVID-19 group, it was found that the Mean IL-6 Post was significantly lower than Pre, which was 23.0 compared to 26.1 (p<0.001), while in the control group, the Mean IL-6 Post (four weeks) was significantly lower than Pre (baseline), which was 19. .3 versus 21.0 (p<0.001). Serum IL-6 levels appeared to be a useful prognostic biomarker in patients with a diagnosis of COVID-19 disease. The cut-off point of 35 pg/mL could differentiate mild-moderate patients from the more severe patients.
Conclusion: We discovered that schizophrenia patients with verified positive COVID-19 received COVID-19 therapy in the form of a combination of antipsychotic and antivirals, were lower than 35 pg/mL, with indicate the role of antipsychotic (risperidone) and antiviral in reduction IL-6 level.
Keywords : COVID-19; Risperidone; Schizophrenia; Positive and Negative Syndrome Scale, Interleukin-6